Skip to main content
. 2022 Feb 5;26(7):1918–1931. doi: 10.1111/jcmm.17214

TABLE 1.

Analysis of LY% in all lung cancer patients

Training cohort No. (%)

Total

(n=667)

p value

20–50

(n=365)

<20

(n=302)

Basic characteristics
Age 0.002**
<45 32(8.7) 17(5.6) 49
45–60 174(47.7) 112(37.1) 286
>60 159(43.6) 173(57.3) 332
Sex 0.013*
Male 229(62.7) 217(71.9) 446
Female 136(37.3) 85(28.1) 221
Histological subtype 0.002**
SCC 75(20.5) 94(31.1) 169
ADC 187(51.2) 151(50.0) 338
SCLC 77(21.1) 42(13.9) 119
Others 26(7.2) 15(5.0) 41
Stage 0.001**
I

43(1.8)

14(4.7) 57
II 34(9.3) 17(5.6) 51
III 86(23.6) 84(27.8) 170
IV 178(48.8) 168(55.6) 346
Unknown 24(6.5) 19(6.3) 43
Smoking status 0.093
Never smoking 176(48.2) 126(41.7) 302
Current or ex‐smoker

189(51.8)

176(58.3) 365
Differentiation 0.001**
Undifferentiated 234(64.1) 215(71.2) 449
Poor

43(11.8)

48(15.9) 91
Moderate 79(21.6) 32(10.6) 111
Well 3(0.8) 1(0.3) 4
Unknown 6(1.7) 6(2.0) 12
Metastasis
Brain 0.976
No 329(90.1) 272(90.1) 601
Yes 36(9.9) 30(9.9) 66
Bone 0.002**
No 314(86) 232(76.8) 546
Yes 51(14.0) 70(23.2) 121
Liver 0.045*
No 341(93.4) 269(89.1) 610
Yes 24(6.6) 33(10.9) 57
Adrenal gland 0.736
No 342(93.7) 281(93.0) 623
Yes 23(6.3) 21(7.0) 44
Lymph node 0.180
No 170(46.6) 125(41.4) 295
Yes 195(53.4) 177(58.6) 372
Intrapulmonary 0.244
No 324(88.8) 259(85.8) 583
Yes 41(11.2) 43(14.2) 84
Pleural 0.000***
No 333(91.2) 248(82.1) 581
Yes 32(8.8) 54(17.9) 86
Mediastinal 0.514
No 356(97.5) 292(96.7) 648
Yes 9(2.5) 10(3.3) 19
Validation cohort No. (%)

Total

(n=645)

p value

20–50

(n=362)

<20

(n=283)

Basic characteristics
Age 0.826
<45 28(7.8) 24(8.5) 52
45–60 167(46.1) 124(43.8) 291
>60 167(46.1) 135(47.7) 302
Sex 0.013*
Male

237(65.5)

211(74.6) 448
Female 125(34.5) 72(25.4) 197
Histological subtype 0.034*
SCC 84(23.2) 87(30.7) 171
ADC 205(56.6) 132(46.6) 337
SCLC 50(13.8) 44(15.5) 94
Others 23(6.4) 20(7.2) 43
Stage 0.000***
I 42(11.6) 13(4.6) 55
II 40(11.1) 19(6.7) 59
III 89(24.6) 71(25.1) 160
IV 159(43.9) 162(57.2) 321
Unknown 32(8.8) 18(6.4) 50
Smoking status 0.338
Never smoking 162(44.8) 116(41.0) 278
Current or ex‐smoker 200(55.2) 167(59.0) 367
Differentiation 0.000***
Undifferentiated 229(63.3) 205(72.4) 434
Poor 43(11.9) 49(17.3) 92
Moderate 87(24.0) 26(9.2) 113
Well 2(0.5) 2(0.7) 4
Unknown 1(0.3) 1(0.4) 2
Metastasis
Brain 0.465
No 331(91.4) 254(89.8) 585
Yes 31(8.6) 29(10.2) 60
Bone 0.029*
No 308(85.1) 222(78.4) 530
Yes 54(14.9) 61(21.6) 115
Liver 0.005**
No 342(94.5) 250(88.3) 592
Yes 20(5.5) 33(11.7) 53
Adrenal gland 0.002**
No 357(98.6) 267(94.3) 624
Yes 5(1.4) 16(5.7) 21
Lymph node 0.020*
No 170(47.0) 107(37.8) 277
Yes 192(53.0) 176(62.2) 368
Intrapulmonary 0.198
No 326(90.1) 263(92.9) 589
Yes

36(9.9)

20(7.1) 56
Pleural 0.037*
No 324(89.5) 239(84.5) 563
Yes 38(10.5) 44(15.5) 82
Mediastinal 0.063
No 358(98.9) 274(96.8) 632
Yes

4(1.1)

9(3.2) 13
*

< 0.05, **< 0.01, ***< 0.001. LY%: lymphocyte percentage; SCC: lung squamous carcinoma; ADC: lung adenocarcinoma; SCLC: small‐cell lung cancer; poor: poorly differentiated; moderate: moderately differentiated; well: well differentiated.